Eton Pharmaceuticals Enters Material Definitive Agreement
Ticker: ETON · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1710340
Sentiment: neutral
Topics: material-agreement
TL;DR
Eton Pharma signed a big deal, details TBD.
AI Summary
Eton Pharmaceuticals, Inc. announced on October 2, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated financial figures.
Why It Matters
This filing indicates a significant new development for Eton Pharmaceuticals, potentially impacting its business operations and future financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Eton Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
When did Eton Pharmaceuticals enter into this material definitive agreement?
The earliest event reported is October 2, 2024.
Are there any financial terms disclosed in relation to this agreement?
No financial terms or amounts are disclosed in this filing.
What is the filing type and date?
This is a Form 8-K filed on October 3, 2024.
What is Eton Pharmaceuticals' primary business sector?
Eton Pharmaceuticals is in the Pharmaceutical Preparations sector, SIC code 2834.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-10-03 06:30:14
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $22.5 million — the Company will purchase Increlex for $22.5 million at closing and will pay an additional $
- $7.5 million — n at closing and will pay an additional $7.5 million for product inventory. The Company will
- $2.5 million — ny will also make payments to Seller of $2.5 million on each of the first and second anniver
- $25.7 million — expand its existing credit facility by $25.7 million to $30.0 million, extend the facility's
- $30.0 m — ing credit facility by $25.7 million to $30.0 million, extend the facility's maturity t
- $5.32 — 36 shares of common stock at a price of $5.32 per share. A copy of the press release
Filing Documents
- eton20240930_8k.htm (8-K) — 29KB
- ex_728717.htm (EX-99.1) — 25KB
- 0001437749-24-030557.txt ( ) — 191KB
- eton-20241002.xsd (EX-101.SCH) — 3KB
- eton-20241002_def.xml (EX-101.DEF) — 11KB
- eton-20241002_lab.xml (EX-101.LAB) — 15KB
- eton-20241002_pre.xml (EX-101.PRE) — 11KB
- eton20240930_8k_htm.xml (XML) — 3KB
01: Entry into a Material Definitive Agreement
Item 1.01: Entry into a Material Definitive Agreement On October 2, 2024, Eton Pharmaceuticals, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Ipsen Biopharmaceuticals, Inc. (the "Seller"), a subsidiary of Ipsen S.A., pursuant to which the Company has agreed to acquire Increlex (mecasermin injection) from Seller. Increlex is a biologic product used to treat children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD) because their bodies do not make enough insulin-like growth factor 1 (IGF-1). The product is approved in 40 territories, including the United States and the European Union. Under the terms of the Purchase Agreement, the Company will purchase Increlex for $22.5 million at closing and will pay an additional $7.5 million for product inventory. The Company will also make payments to Seller of $2.5 million on each of the first and second anniversaries of closing. In addition, the Company will be obligated to purchase additional inventory over 30 months, in an amount not to exceed 15.0 million. The acquisition is structured as an all-cash purchase without any financing contingencies and is expected to close near year-end 2024, subject to customary closing conditions. Each of the Company and Seller have made customary representations, warranties, covenants and indemnities in the Purchase Agreement. As part of the acquisition, the parties have entered into a transition services agreement, whereby Seller will continue to distribute the product in markets outside the United States for a period of six months following the closing. The Company will immediately commercialize the product within the United States upon closing. The Company also entered into an amendment to its existing credit agreement with SWK Holdings that is contingent upon the closing of the Purchase Agreement. Under the terms of the amendment, the Company will expand its existing credit facility by $25.7 million to $30
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated October 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4